NCT06141356View on ClinicalTrials.gov

[18F]Florbetazine ([18F]92) for Beta Amyloid PET Imaging in Alzheimer's Disease

RecruitingOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

January 30, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Alzheimer's Disease
Interventions
DRUG

[18F]Florbetazine ([18F]92)

Participants will receive a single intravenous bolus injection of 10 mCi ± 20% of the investigational radiotracer \[18F\]Florbetazine and will undergo a PET/CT scan.

DRUG

[11C]PIB

Participants will receive a single intravenous bolus injection of 6.0-20.0mCi of the investigational radiotracer \[11C\]PIB and will undergo a PET/CT scan.

Trial Locations (1)

100730

RECRUITING

Department of Nuclear Medicine, Peking Union Medical College Hopital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER